KFSH

King Faisal Specialist Hospital & Research Centre Leading Health Sector Transformation in Saudi Arabia

Retrieved on: 
Thursday, May 9, 2024
Public, Genetics, RC, Malaria, Health, Cardiology, WGS, KFSH, ANFAL, Organ transplantation, Conditional sentence, Life expectancy, Harmony, TPV, Harvard University

RIYADH, Saudi Arabia, May 09, 2024 (GLOBE NEWSWIRE) -- Harvard University -- Eight years into Vision 2030, Saudi Arabia has made significant strides with digital innovations and enhanced access to quality care.

Key Points: 
  • RIYADH, Saudi Arabia, May 09, 2024 (GLOBE NEWSWIRE) -- Harvard University -- Eight years into Vision 2030, Saudi Arabia has made significant strides with digital innovations and enhanced access to quality care.
  • These efforts have notably raised the average life expectancy, reduced mortality rates, and enhanced overall well-being across the Kingdom.
  • KFSH&RC’s digital health initiatives extend to addressing broader health threats through technologies such as Whole Genomic Sequencing (WGS) and Advanced Radiation Therapy.
  • Additionally, KFSH&RC stands out as the only hospital worldwide to be ranked among its country's top ten most valuable brands.

KFSH&RC Ranked Top Valuable Healthcare Brand in Saudi Arabia and Middle East

Retrieved on: 
Thursday, May 2, 2024
RC, Hospital, KFSH, Royal Highness, Patient, Health, Crown prince, Newsweek, Corporate communication, Saudi Vision 2030, Academic Medical Center (Amsterdam)

RIYADH, Saudi Arabia, May 02, 2024 (GLOBE NEWSWIRE) -- KFSH&RC tops the healthcare sector in the Kingdom of Saudi Arabia and the Middle East, recognizing it as the most valuable healthcare brand in these regions for the second year.

Key Points: 
  • RIYADH, Saudi Arabia, May 02, 2024 (GLOBE NEWSWIRE) -- KFSH&RC tops the healthcare sector in the Kingdom of Saudi Arabia and the Middle East, recognizing it as the most valuable healthcare brand in these regions for the second year.
  • According to the 2024 Brand Finance reports, it placed 9th in Saudi Arabia and 28th in the Middle East.
  • Additionally, KFSH&RC stands out as the only hospital worldwide to be ranked among its country's top ten most valuable brands.
  • The Brand Finance Report shows that KFSH&RC brand value increased by 31%, exceeding 5.6 billion Saudi Riyals, equivalent to USD 1.5 billion.

KFSH&RC Announced as Strategic Partner for the Saudi American Healthcare Forum 2024

Retrieved on: 
Tuesday, April 23, 2024
RC, Hospital, Medicine, Research, Innovation, KFSH, Business, Newsweek, Ministry

RIYADH, Saudi Arabia, April 23, 2024 (GLOBE NEWSWIRE) -- KFSH&RC participates as a strategic partner in the Saudi American Healthcare Forum, which will take place on April 25th under the patronage of the Ministry of Health in Riyadh. This forum aims to discuss the primary healthcare challenges facing the American and Arab populations and to support collaboration, innovation, and healthcare partnerships between the two nations.

Key Points: 
  • RIYADH, Saudi Arabia, April 23, 2024 (GLOBE NEWSWIRE) -- KFSH&RC participates as a strategic partner in the Saudi American Healthcare Forum, which will take place on April 25th under the patronage of the Ministry of Health in Riyadh.
  • This forum aims to discuss the primary healthcare challenges facing the American and Arab populations and to support collaboration, innovation, and healthcare partnerships between the two nations.
  • The forum will focus on key topics that contribute to the development of healthcare, in addition to creating a platform for bilateral information exchange, exploring cooperation opportunities, and sharing best practices in global healthcare.
  • The Saudi American Healthcare Forum will feature a broad attendance, including top businessmen, academics, and industry experts from both countries, to enhance initiatives and solutions, and support the existing bilateral relations based on "Healthcare Diplomacy".

KFSH&RC Welcomes Dr. Björn Zoéga as New Deputy CEO

Retrieved on: 
Tuesday, April 2, 2024
Karolinska University Hospital, Health, Education, Research, RC, Karolinska Institute, Landspítali, KFSH, National University Hospital

RIYADH, Saudi Arabia, April 02, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH&RC) is proud to announce the appointment of Dr. Björn Zoéga as Deputy Chief Executive Officer (CEO), effective 01 April 2024. This strategic move is set to accelerate KFSH&RC's aspiration of becoming a leading healthcare institution on the global stage, leveraging Dr. Zoéga's notable career and proven track record of leadership in top-tier medical institutions.

Key Points: 
  • RIYADH, Saudi Arabia, April 02, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH&RC) is proud to announce the appointment of Dr. Björn Zoéga as Deputy Chief Executive Officer (CEO), effective 01 April 2024.
  • His administration at Karolinska was marked by innovative strategies and excellence in healthcare delivery—all which he is posed to enrich within KFSH&RC.
  • Dr. Zoégabrings decades of healthcare management and clinical expertise to KFSH&RC, having spearheaded operations as CEO of the National University Hospital of Iceland and the Stockholm Spine Center.
  • As Deputy CEO, Dr. Zoéga will serve as chief lead of KFSH&RC’s healthcare delivery and research and innovation groups, following on the hospital’s commitment to integrating global best practices in healthcare and pursuing cutting-edge medical research and technology.

To Bolster Global Efforts in Combating Antibiotic-Resistant Bacteria KFSH&RC Scientists Discover New Bacteria Species: Riyadhensis

Retrieved on: 
Monday, March 25, 2024
WGS, Health, Disease, Education, Patient, Research, Hospital, Bacteria, Pseudomonas aeruginosa, RC, KFSH, Infection, Intensive care medicine, Newsweek, ICU, Vaccine

RIYADH, Saudi Arabia, March 25, 2024 (GLOBE NEWSWIRE) -- In a ground-breaking development, scientists at King Faisal Specialist Hospital and Research Centre (KFSH&RC) have identified a new species of bacteria, referred to as "Stenotrophomonas Riyadhensis" through the application of whole-genome sequencing (WGS) technology. This discovery signifies a major advancement in understanding how bacteria interact with existing drugs, paving the way for innovative therapeutic strategies. Such efforts are essential in the global fight against antibiotic-resistant bacteria, highlighting KFSH&RC’s advanced research capabilities and its leading role in fostering scientific discoveries and enhancing patient care.

Key Points: 
  • This discovery signifies a major advancement in understanding how bacteria interact with existing drugs, paving the way for innovative therapeutic strategies.
  • Such efforts are essential in the global fight against antibiotic-resistant bacteria, highlighting KFSH&RC’s advanced research capabilities and its leading role in fostering scientific discoveries and enhancing patient care.
  • This represents substantial progress in combating antibiotic resistance, developing pharmaceuticals, and preventing the spread of diseases.
  • Furthermore, this approach lays the groundwork for scientific collaboration at all levels, enhancing global efforts to combat antibiotic resistance.

King Faisal Specialist Hospital & Research Centre Holds Firm as Global and Regional Healthcare Leader

Retrieved on: 
Thursday, February 15, 2024
King Fahd University Hospital, Hospital, King Fahd Medical City, Education, National Guard Health Affairs, Health, KFSH, Vision 2030, RC, Kingdom

RIYADH, Saudi Arabia, Feb. 15, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH&RC) has once again secured its position for the second consecutive year as a global leader in healthcare and number one in the Middle East and Africa, ranking 20th globally among the leading healthcare institutions in the Brand Finance Global Top 250 Hospitals 2024 report. KFSH&RC continues to stand at the forefront both locally and regionally, underlining its commitment to delivering world-class patient-centric healthcare and medical innovation.

Key Points: 
  • KFSH&RC continues to stand at the forefront both locally and regionally, underlining its commitment to delivering world-class patient-centric healthcare and medical innovation.
  • Leading the way, KFSH&RC is joined by King Saud Medical City, King Khalid University Hospital, National Guard Health Affairs, and King Fahd Medical City, all ranked among the top 100 globally.
  • While King Fahd University Hospital and King Abdullah Medical City rank between 101 and 250.
  • King Faisal Specialist Hospital & Research Centre stands among the global leaders in providing specialized healthcare, driving innovation, and serving as an advanced hub for medical research and education.

Researchers at KFSH&RC & KAUST Discover Gene Responsible for Reproduction of the Most Dangerous Malaria Strain

Retrieved on: 
Monday, February 5, 2024
Parasitism, Research, Immune system, Bacteria, KFSH, KAUST, Nature, Diagnosis, Medical laboratory, Pathology, RC, Plasmodium falciparum, Health, Malaria, Vaccine

RIYADH, Saudi Arabia, Feb. 05, 2024 (GLOBE NEWSWIRE) -- In a major scientific breakthrough, a research team from King Faisal Specialist Hospital and Research Centre (KFSH&RC), in collaboration with King Abdullah University of Science and Technology (KAUST), working alongside researchers from the UK, the US, and India, discovered a vital gene instrumental in combating malaria. This gene, termed PfAP2-MRP, is essential in the replication process of Plasmodium falciparum, the parasite that causes the most lethal strain of malaria.

Key Points: 
  • This gene, termed PfAP2-MRP, is essential in the replication process of Plasmodium falciparum, the parasite that causes the most lethal strain of malaria.
  • Advanced laboratory techniques enabled the researchers to inhibit the PfAP2-MRP gene, revealing its critical role in the malaria parasite’s life cycle within red blood cells.
  • This inhibition significantly disrupts the parasite’s ability to reproduce, reducing the severity of the disease’s symptoms and curbing its spread.
  • This discovery is particularly impactful as it addresses Plasmodium falciparum malaria, which claims over half a million lives annually.

KFSH&RC-Madinah Receives Prestigious 2023 Press Ganey Human Experience Guardian of Excellence Award

Retrieved on: 
Monday, January 29, 2024
Organ transplantation, Patient, Newsweek, KFSH, History, Genetics, GM, Neuroscience, Cancer, Safety, Health, RC, Nursing

RIYADH, Saudi Arabia, Jan. 29, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH&RC) in Madinah has won the 2023 Human Experience Guardian of Excellence Award by Press Ganey for its exceptional performance in outpatient services throughout the past year. This prestigious recognition honored a distinguished group of healthcare institutions, from approximately 1500 facilities globally, for being amongst the top 5% performers in patient experience in one year.

Key Points: 
  • RIYADH, Saudi Arabia, Jan. 29, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH&RC) in Madinah has won the 2023 Human Experience Guardian of Excellence Award by Press Ganey for its exceptional performance in outpatient services throughout the past year.
  • This prestigious recognition honored a distinguished group of healthcare institutions, from approximately 1500 facilities globally, for being amongst the top 5% performers in patient experience in one year.
  • Through this award, Press Ganey, a leading global organization in measuring and enhancing patient experience, reflects KFSH&RC's commitment to delivering top-tier healthcare solutions and outstanding patient experiences across various healthcare services within an integrated education and research setting.
  • The 2023 Press Ganey Award ceremony is set to be announced later in February.

KFSH&RC Celebrates 25 Scientists Named in Stanford's Top 2% Most-Cited Researchers Worldwide

Retrieved on: 
Wednesday, January 24, 2024
Knowledge, Stanford University, Excellency, Vision 2030, KFSH, Research, RC, Pharmaceutical industry

RIYADH, Saudi Arabia, Jan. 24, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre honored 25 scientists who joined Stanford University's prestigious list, marking them among the 'top 2% most-cited scientists' list updated in October 2023.

Key Points: 
  • The recent release recognizes 25 distinguished KFSH&RC scientists, among the top 2% most-cited researchers worldwide in 2021-2022, and acknowledges their overall career accomplishments.
  • This prestigious recognition celebrates the outstanding contributions and impact of KFSH&RC researchers on the global scientific stage, highlighting KFSH&RC's steady commitment to advancing healthcare through novel research.
  • This new milestone reflects the dedication and expertise of our exceptional team of scientists and medical professionals who continually push the boundaries of knowledge.
  • The university unveils a list featuring 180,000 researchers representing the top 2% of most-cited scientists globally each year.

Vertex Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) in Kingdom of Saudi Arabia

Retrieved on: 
Tuesday, January 9, 2024
Health, Genetics, Clinical Trials, General Health, Pharmaceutical, Biotechnology, SCD, Vertex Pharmaceuticals, Patient, KFSH, Kingdom, Hospital, CRISPR, Authorization, Medicine, Sickle cell disease, TDT, SFDA, Marketing, ATC, VRTX, Prevalence, Pharmaceutical industry

CASGEVY is approved for the treatment of people 12 years of age and older with SCD or TDT.

Key Points: 
  • CASGEVY is approved for the treatment of people 12 years of age and older with SCD or TDT.
  • The Kingdom of Saudi Arabia has among the highest prevalence rates of SCD and TDT in the world, with thousands of patients living with these genetic blood disorders.
  • Vertex is working to qualify additional hospitals as ATCs to bring CASGEVY to patients, including the King Faisal Specialist Hospital (KFSH).
  • In order to enable rapid access to CASGEVY, Vertex is working to secure listing on hospital formularies to support reimbursement as soon as possible.